Step-wise vs rapid escalator approach for PsO & PsA? ⭐️CONTROL study: ➡️bDMARD-naive active PsA w/ IR to MTX for at least 4w randomized to ADA+MTX vs escalated MTX (avg dose 21.8 mg/wk, 55% PO, 36% SQ) ➡️41.5% MDA at wk 16 w/ ADA+MTX vs 13.1% #EULAR2021 @RheumNow https://t.co/uw5BFQGqNV